CompletedPhase 2NCT03041038
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Studying Autosomal recessive congenital ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Amy Paller, MD, MDNorthwestern University Department of Dermatology
- Intervention
- Secukinumab(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2020
Study locations (2)
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- Department of Dermatology Icahn School of Medicine at Mount Sinai, New York, New York, United States
Collaborators
Icahn School of Medicine at Mount Sinai
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03041038 on ClinicalTrials.gov